EARLY APPLICATION OF HIGH CUT-OFF HAEMODYALISIS FOR DE-NOVO MYELOMA NEPHROPATHY IS ASSOCIATED WITH LONG-TERM DIALYSIS-INDEPENDENCY AND RENAL RECOVERY

Alhossain A. Khalafallah, Sie Wuong Loi, Sarah Love, Muhajir B. Mohamed, Rose Mace, Ramy Khalil, Miriam Girgs, Rajesh Raj, Mathew Mathew
  • Alhossain A. Khalafallah
    Launceston General Hospital School of Human Life Sciences, University of Tasmania, Australia | alhossain@yahoo.com
  • Sie Wuong Loi
    The Launceston General Hospital Launceston, Australia, Australia
  • Sarah Love
    Faculty of Health and Life Sciences, Coventry University, Coventry, West Midlands, UK., United Kingdom
  • Muhajir B. Mohamed
    The Launceston General Hospital Launceston, Australia, Australia
  • Rose Mace
    The Launceston General Hospital Charles Street Launceston, TAS 7250 Australia, Australia
  • Ramy Khalil
    The Launceston General Hospital Charles Street Launceston, TAS 7250 Australia, Australia
  • Miriam Girgs
    The Launceston General Hospital Charles Street Launceston, TAS 7250 Australia, Australia
  • Rajesh Raj
    The Launceston General Hospital Charles Street Launceston, TAS 7250 Australia, Australia
  • Mathew Mathew
    The Launceston General Hospital Charles Street Launceston, TAS 7250 Australia,

Abstract

Background

Multiple myeloma (MM) is a haematological malignancy associated with kidney injury resulting from cast nephropathy, which can be caused by monoclonal free light chains (FLC). It has been demonstrated that reduction of FLC can lead to a higher proportion of patients recovering renal function with a better outcome, especially if extended high cut-off haemodialysis (HCO-HD) combined with chemotherapy is used.

Patients and Methods

In this study, four cases of MM nephropathy were treated with HCO-HD and chemotherapy at a single institution during the period from August 2009 to August 2011. All of the patients presented with acute renal failure and high serum FLC. All patients underwent a bone marrow biopsy to confirm the diagnosis of MM, according to the WHO criteria. Three patients had de-novo MM and one patient had relapsed light chain myeloma disease. All patients underwent HCO-HD concomitantly with specific myeloma therapy once the diagnosis or relapse of MM was established.

Results

After a median follow up of 26 months, (range, 13-36) our data showed that all patients had a significant decrease in serum FLC through HCO-HD, proving the effectiveness of HCO-HD in managing MM. De-novo MM patients restored their renal function and achieved low-level FLC early on the treatment and become dialysis-independent. One patient with relapsed myeloma remained dialysis dependant.

Conclusion

Our study suggests that if myeloma nephropathy associated with light-chain disease, HCO-HD should be initiated as early as possible. At the same time a specific MM treatment should be initiated to gain control of the disease and salvage the kidneys in order to achieve dialysis-independency. Further trials to confirm our results are warranted.

Key Words: Multiple myeloma, renal failure, High cut-off haemodialysis, chemotherapy, outcome.

Keywords

Multiple myeloma, renal failure, High cut-off haemodialysis, chemotherapy, outcome.

Full Text:

PDF
HTML
Submitted: 2014-06-13 09:56:32
Published: 2013-01-02 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
248

Views:
PDF
99
HTML
1633

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Ā 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPressĀ®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185